Telix Pharmaceuticals (ASX:TLX) said the first patient has been administered its drug candidate TLX300-CDx in the Phase 1 ZOLAR1 trial for advanced metastatic soft tissue sarcoma (STS), according to a Tuesday statement by the company.
The trial aims to assess the drug's biodistribution, safety, and optimal dose using positron emission tomography (PET), the statement said.
TLX300-CDx targets PDGFRα, a protein often over-expressed in STS, the statement added.
The study will inform future therapeutic approaches for treating the disease, the company said.
Telix holds the rights to develop and commercialize the radiolabelled drug, the company added.
Shares of the company fell 3% on market close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.